“…Due to its small size of 17.8 kDa, myoglobin is quickly released into circulation within 1 -3 h after symptom onset, and serves as a valuable screening molecule with high sensitivity and predictivity for AMI detection. [3][4][5] Optical biosensors, including a sandwich immunoassay with secondary labeled antibodies, enzyme-linked immunosorbent assay (ELISA), fluorescence, and surface plasma resonance (SPR), have been used for the detection of cardiac markers, such as troponin I, myoglobin, c-reactive protein (CRP), and myeloperoxidase (MPO). [6][7][8][9][10] Driven by a clinical need for pointof-care diagnostics, next-generation biosensors with improved sensitivity and specificity have attracted increasing attention in recent years, leading to the development of peptide-based sensing approaches.…”